IPROOV
20.5.2020 09:02:10 CEST | Business Wire | Press release
iProov , the world leader in spoof-resistant, biometric authentication technology, today announced that its technology has been deployed to verify users signing up to NHS login across Android and iOS. Following an initial launch on Android, iProov’s technology is now available on the iOS version of the NHS App.
This enables users in England to create their NHS login remotely, securely and conveniently at a time when they need it most, removing the need for manual and in-person verifications. The NHS App allows for easy and fast access to essential services such as GP appointments, access to medical records and ordering repeat prescriptions.
iProov’s Flashmark facial verification technology is now used by users to create an NHS login through the NHS App. Once a user submits a photo of their identity document, such as a valid passport or driving licence, they will be prompted to position their face correctly on the screen. Following a short sequence of flashing colours, the user’s identification will be verified and they will be able to access all the information and services the NHS App has to offer, following completion of all other checks including matching a user to their medical record.
The iProov process verifies that an individual is a real person, the right person, and is authenticating themselves right now. This protects against the risk of identity theft while giving people quicker and more convenient access to vital services wherever they are. It also frees up valuable NHS resources and saves money, as NHS Digital now needs to process far fewer manual applications. More than a million people have now registered with NHS login, with a peak of over 60,000 new IDs verified during the first week of April. The combined iProov and NHS solution has proven its ability to cope with an unprecedented increase in demand.
Andrew Bud, Founder and CEO, iProov said: “The NHS login service is now a proven, secure, inclusive and effective way for citizens to verify and use their identity for health-related purposes. We have been very impressed by what the NHS Digital team has accomplished, by their agility and professionalism, and by the boldness of their vision.
“This is particularly important in the current climate in which demand is unprecedented and the need for convenient and robust remote identity verification is crucial. We are delighted to be playing our part.”
Melissa Ruscoe, Programme Head for NHS login, said: “iOS users are now able to benefit from faster automatic identity verification when creating their NHS login, giving them a single safe and secure way to access their digital healthcare services such as the NHS App.
“Over the past couple of months we have seen a surge in demand in people registering for an NHS login as they look to manage their health digitally.
“More automated tools like this will help us to improve the experience of our users, increase demand capacity and ensure nobody is waiting too long to complete identity verification checks to gain access to their digital healthcare services.”
In addition to NHS login, iProov’s unique patented technology is used to verify identities in the Home Office ‘EU Exit: ID Document Check’ app which enables European citizens to apply to the EU Settlement Scheme. iProov also provides governments, banks and other enterprises with Genuine Presence Assurance, including the US Department for Homeland Security, allowing them to authenticate users remotely on smartphones or other devices.
ENDS
About iProov
Founded in 2011, iProov is a world leader in spoof-resistant, biometric facial authentication technology. Its technology is used by banks and governments around the world for secure customer onboarding, logon and authentication, to ensure new and returning users are genuine, and to guard against fraudulent attempts to gain access to personal data. For more information, see www.iproov.com
.
About NHS login
NHS login is a service that has been created by the NHS for patients and the public. It provides a re-usable way for patients to access multiple digital health and social care services with a single login, which includes authentication for returning users.
NHS login can be used by the public to securely access their health and care information wherever they see the NHS login button. People can use NHS login to prove who they are safely and securely and, in most cases, without the need to visit their GP.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200520005254/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
